Literature DB >> 15056236

Role of serum neutralizing antibody in reinfection of respiratory syncytial virus.

Yukihiko Kawasaki1, Mitsuaki Hosoya, Masahiko Katayose, Hitoshi Suzuki.   

Abstract

BACKGROUND: To clarify the role of serum antibody in respiratory syncytial virus (RSV) reinfection, the authors conducted a follow-up study of patients with primary RSV infection.
METHODS: From 1994 to 1995, 256 patients were a diagnosed with primary RSV infection based on the antigen detection in nasopharyngeal secretions using enzyme linked immunoassay method. One hundred and sixty-five patients were followed-up for 1 year, and 87 of the 165 patients showed respiratory symptoms in winter. When a patient had a symptom such as cough, wheezing, rhinorrhea or fever, the nasopharyngial secretion was examined for the presence of RSV. Forty-one patients (group 1) were diagnosed with reinfection with RSV and the other 46 patients (group 2) were not diagnosed with reinfection. The authors compared clinical features between primary infection and reinfection of group 1 and serum neutralization test (NT) antibody titers to RSV between group 1 and 2.
RESULTS: The mean age was 6.0 +/- 3.6 months at RSV primary infection and 14.6 +/- 8.2 months at RSV reinfection. Hospitalization, oxygen supplementation, and use of respirator were required by 71%, 39%, 2%, respectively, in primary infection, and by 22%, 0%, 0%, respectively, in reinfection. All children in group 1 had titers of 1 : 16 or lower, while 39.1% of children in group 2 had titers of 1 : 16 or lower (P < 0.05). No patient with the titers of 1 : 32 or higher had symptomatic reinfection. Serum NT antibodies to RSV of outpatients were higher than those of inpatients at reinfection.
CONCLUSIONS: The severity of illness in RSV reinfection is generally milder than that in primary infection. Our findings suggest that NT antibodies play an important role in reducing the severity of illness as well as in protection from RSV reinfection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15056236     DOI: 10.1046/j.1442-200x.2004.01860.x

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  12 in total

1.  Characterization of Pre-F-GCN4t, a Modified Human Respiratory Syncytial Virus Fusion Protein Stabilized in a Noncleaved Prefusion Conformation.

Authors:  Normand Blais; Martin Gagné; Yoshitomo Hamuro; Patrick Rheault; Martine Boyer; Ann-Muriel Steff; Guy Baudoux; Vincent Dewar; Josée Demers; Jean-Louis Ruelle; Denis Martin
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

2.  Molecular analysis of respiratory syncytial virus reinfections in infants from coastal Kenya.

Authors:  Paul D Scott; Rachel Ochola; Mwanajuma Ngama; Emelda A Okiro; D James Nokes; Graham F Medley; Patricia A Cane
Journal:  J Infect Dis       Date:  2005-11-17       Impact factor: 5.226

3.  Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cells.

Authors:  Pablo A González; Carolina E Prado; Eduardo D Leiva; Leandro J Carreño; Susan M Bueno; Claudia A Riedel; Alexis M Kalergis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-25       Impact factor: 11.205

4.  From bronchiolitis guideline to practice: A critical care perspective.

Authors:  James A Lin; Andranik Madikians
Journal:  World J Crit Care Med       Date:  2015-08-04

5.  Respiratory syncytial virus (RSV) infection in children with medical complexity.

Authors:  A Lim; M L Butt; J Dix; L Elliott; B Paes
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-10-29       Impact factor: 3.267

6.  Respiratory Syncytial Virus Aggravates Renal Injury through Cytokines and Direct Renal Injury.

Authors:  Songhui Zhai; Lijuan Hu; Lin Zhong; Yannan Guo; Liqun Dong; Ruizhen Jia; Zheng Wang
Journal:  Front Cell Infect Microbiol       Date:  2016-09-30       Impact factor: 5.293

Review 7.  Current concepts and progress in RSV vaccine development.

Authors:  Aleks K Guvenel; Christopher Chiu; Peter Jm Openshaw
Journal:  Expert Rev Vaccines       Date:  2014-01-09       Impact factor: 5.683

8.  Mode of parainfluenza virus transmission determines the dynamics of primary infection and protection from reinfection.

Authors:  Crystal W Burke; Olga Bridges; Sherri Brown; Richard Rahija; Charles J Russell
Journal:  PLoS Pathog       Date:  2013-11-21       Impact factor: 6.823

9.  Factors Contributing to Symptom Duration and Viral Reduction in Outpatient Children With Respiratory Syncytial Virus Infection.

Authors:  Takeshi Utsunomiya; Akinobu Hibino; Kiyosu Taniguchi; Takao Nagai; Naruo Saito; Ikumi Tanabe; Takashi Odagiri; Yugo Shobugawa; Akira Kaneko; Reiko Saito
Journal:  Pediatr Infect Dis J       Date:  2020-08       Impact factor: 3.806

Review 10.  Contribution of Dendritic Cells in Protective Immunity against Respiratory Syncytial Virus Infection.

Authors:  Hi Eun Jung; Tae Hoon Kim; Heung Kyu Lee
Journal:  Viruses       Date:  2020-01-15       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.